Achiko AG Signs Major Marketing and Sales Agreement with World’s Largest Islamic Association for its AptameX Covid-19 Rapid Test
20. April 2022 07:45 ET
|
Achiko AG
Signed major deal with Pengurus Wilayah Nahdlatul Ulama DKI Jakarta, for the use of Covid-19 test AptameX in general assemblies and activities. Located primarily in Indonesia, Nahdlatul Ulama is the...
Achiko AG Looks Back at Pivotal Year and Reaffirms Commitment to Provide Affordable and Accurate COVID-19 Testing Solution
23. Dezember 2021 07:30 ET
|
Achiko AG
2021 Was a Pivotal Year for Achiko, Marked by Seminal Developments and ApprovalsWith AptameX™, Achiko Launched an Innovative DNA Aptamer Saliva-Based Rapid Test for Covid-19 as an Affordable and...
Achiko AG’s Shares Begin Trading on the OTCQB Market
20. Dezember 2021 07:30 ET
|
Achiko AG
ZURICH, Switzerland, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468; www.achiko.com) (“Achiko”, the “Company”), a global healthtech company which has...
Achiko’s Position on Omicron Variant
02. Dezember 2021 07:30 ET
|
Achiko AG
The chemical mode of action of AptameX, Achiko's rapid Covid-19 test, strongly suggests that Omicron can be detected as reliably as any other Covid-19 variant known to dateAchiko’s highly effective,...
Achiko’s Rapid Covid-19 Diagnostic Test AptameX™ Receives Product and Registration Approval from Indonesia’s Ministry of Health
25. August 2021 07:30 ET
|
Achiko AG
AptameX™, Achiko’s breakthrough DNA aptamer-based diagnostic test for Covid-19, received product and registration emergency use approval from the Ministry of Health in Indonesia, alongside its sister...
Achiko Engages EpiMetrics to Expand Covid-19 Testing Operations with Udayana University in Bali, Indonesia in the Implementation of a Mass Testing Program
15. Juli 2021 07:30 ET
|
Achiko AG
ZURICH, Switzerland, July 15, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SWX:ACHI, ISIN CH0522213468) (“Achiko”, the “Company”), a global healthtech company...
Achiko Working Towards a Solution for Frequent Global Mass COVID-19 Testing
13. Juli 2021 07:30 ET
|
Achiko AG
ZURICH, Switzerland, July 13, 2021 (GLOBE NEWSWIRE) -- Achiko AG (SWX:ACHI, ISIN CH0522213468) (“Achiko”, the “Company”), a global healthtech company currently developing technologies that seek to...
Achiko Announces an Extension of its Convertible Loan Transaction with Negma Group
18. Juni 2021 12:01 ET
|
Achiko AG
ZURICH, June 18, 2021 (GLOBE NEWSWIRE) -- Achiko AG (SWX:ACHI, ISIN CH0522213468) (“Achiko”, the “Company”) has successfully extended the subordinated convertible loan agreement of CHF 900,000 dated...
Achiko Appoints New Chief Financial Officer and Announces Changes to Senior Team
04. Mai 2021 07:30 ET
|
Achiko AG
Appoints Robert Rieder as Chief Financial OfficerChief Operating Officer Chris Young to Retire Focus on Product Development, Lowering Cost Profile and Improved Alignment of Resources ZURICH,...
Achiko’s Joint Venture Partner Obtains a Distribution Certificate for AptameX, a Novel Diagnostic Test for Covid-19 in Indonesia, and Commences Product Registration
29. April 2021 07:30 ET
|
Achiko AG
Achiko AG’s Joint Venture Partner PT Indonesia Farma Medis (IFM) Obtains Medical Device Distribution CertificateAchiko Subsequently Commenced Product Registration with its Partners with a View to...